In addition to stimulating fat breakdown, AOD-9604 has been studied for anti-lipogenic effects — the inhibition of new fat synthesis. Research in rodent models showed that AOD-9604 treatment reduced the activity of lipogenic enzymes including fatty acid synthase and acetyl-CoA carboxylase in liver and adipose tissue.³

This dual action — promoting fat breakdown while inhibiting new fat formation — represents a different research approach compared to compounds that only affect one side of the energy balance equation.

A separate line of AOD-9604 research has investigated its effects on cartilage. Studies in rabbit and rat models of cartilage injury showed that AOD-9604 promoted chondrocyte (cartilage cell) proliferation and stimulated proteoglycan synthesis, which is a component of the cartilage extracellular matrix. This research led to the compound being investigated for potential applications in osteoarthritis models.⁴

An FDA-approved injectable product (Peptide Bioregulator) containing AOD-9604 exists for use in certain clinical contexts, though OSYRIS AOD-9604 is a research-grade compound sold exclusively for laboratory research.

A significant focus of AOD-9604 research has been demonstrating what it does NOT do — specifically, it does not stimulate IGF-1 production, does not affect blood glucose levels, does not promote organ growth, and does not alter insulin sensitivity. These "negative findings" are scientifically important because they confirm that the fat-metabolizing effects of GH can be isolated from its other biological activities.⁵

Clinical trial data (Phase 2b) published in the International Journal of Obesity examined oral AOD-9604 in overweight individuals and confirmed no effects on IGF-1, insulin, glucose, or cortisol. While the primary efficacy endpoint was not met in that particular trial design, the safety data contributed to the compound's regulatory pathway for other indications.